The (Hotchin et al., 1990) .
Endemic BL is a monoclonal B cell tumour characterised by the presence of a human herpesvirus, Epstein-Barr virus (EBV) and a chromosome translocation involving the c-myc proto-oncogene on chromosome 8 and the IgH locus on chromosome 14, or, more rarely the Ig ic or k loci on chromosome 2 or 22 (Lenoir, 1986) . The result of such a translocation is constitutive activation of the c-myc gene. It is widely accepted that other co-factors must be involved in the aetiology of endemic BL, a prime candidate being malaria which is holoendemic in regions where the endemic form of BL is found (Kafuko & Burkitt, 1970) .
C-Myc is a nuclear protein with homology to a number of sequence-specific DNA-binding proteins (Cole, 1990) . Recent data has indicated that c-Myc forms a heterodimeric complex with a protein called Max, and that this complex acts a sequence-specific transcriptional activating factor (Blackwood & Eisenman, 1991; Amati et al., 1992; Kretzner et al., 1992) . Until recently the role of c-myc in both normal and malignant cells was unclear. Myc is clearly important in cellular proliferation, being expressed at low or undetectable levels in resting or quiescent cells, but induced to high levels in mitotically activated cells (Kelly et al., 1983) . Furthermore anti-sense transcripts have been used to demonstrate that c-myc is required for cell proliferation (Prochownik et al., 1988) . More recently, it has been shown that, in the presence of high levels of c-Myc, cells are unable to withdraw from the cell cycle, and when deprived of nutrients undergo programmed cell death (apoptosis) . On the basis of these data Evan et al. (1992) propose a model for myc function whereby c-myc provides a fail-safe mechanism to prevent uncontrolled proliferation and acts as a regulator of cell fate.
Deregulated c-myc expression is found in a number of mammalian tumours (Spencer & Groudine, 1991) indicating the potential importance of this gene in tumorigenesis. Early experiments, introducing exogenous activated c-myc genes into fibroblasts, resulted in an immortalised, but not fully transformed, phenotype (Land et al., 1983; Mougneau et al., 1984; Land et al., 1986 the Ig;t promoter resulted in the development of B cell lymphomas (Adams et al., 1985) . The monoclonality of these tumours, however, suggested that other factors in addition to activation of c-myc were necessary for development of these tumours. This was supported by data from co-transfection experiments demonstrating cooperation between myc and ras resulting in a transformed phenotype (Land et al., 1986 ). More recently it has been shown that c-Myc induced apoptosis can be overcome by constitutive expression of the bcl-2 proto-oncogene (Fandini et al., 1992; Bissonnette et al., 1992) which is known to inhibit apoptosis in B-cells (Vaux et al., 1988; Hockenbury et al., 1990) . Interestingly, whilst expression of bcl-2 could rescue cells from apoptosis and allow indefinite proliferation in the absence of mitogenic stimuli, morphological transformation was not evident (Fandini et al., 1992) . The majority of EBV infections are subclinical and occur early in life, with over 90% of the adult population demonstrating evidence of past infection (Henle & Henle, 1979) . If primary infection is delayed past the age of 12 years then a common consequence of infection with EBV is infectious mononucleosis (IM), a usually benign, self-limiting lymphoproliferative disease. EBV is also associated with a number of other pathological conditions, including nasopharyngeal carcinoma (NPC), oral hairy leukoplakia and lymphoproliferative disease in patients with severe T-cell immunosuppression. In common with other herpesviruses, EBV persists for life following primary infection, and is tightly controlled by the cell mediated immune response (Rickinson, 1986) .
The role of EBV in development of BL is unclear. EBV is able to immortalise B cells in vitro to form lymphoblastoid cell lines (LCL) which express a number of latency associated proteins -EB nuclear antigens (EBNA-1-6), the latent membrane protein (LMP) and two terminal proteins (TP1 and TP2) (reviewed in Kieff & Liebowitz, 1990) . However, the two viral proteins implicated in this process, EBNA-2 (Hammerschmidt & Sugden, 1989) and LMP (Wang et al., 1985; Baichwal & Sugden, 1985) are not expressed in BL (Rowe et al., 1987a) . LMP has also been shown to upregulate expression of bcl-2 and prevent apoptosis in BL cell lines (Henderson et al., 1991) . However, Bcl-2 is unlikely to be involved in development of BL as it is expressed only at low or undetec- stitutively activated c-myc gene had altered surface phenotype and a reduced serum dependency, they were not transformed as determined by growth in semi-solid media and tumour formation in nude mice (Hotchin et al., 1990 . Both of these markers are typically found in IM in humans and, at least in terms of the serological response to EBV, infection of common marmosets mimics the asymptomatic infection seen in humans (Niederman et al., 1970; Henle & Henle, 1979) . Unlike cotton-top marmosets (Saguinus oedipus oedipus), common marmosets do not develop lymphoproliferative or malignant lesions in response to inoculation with EBV (Miller, 1979; Wedderburn et al., 1984) , thus the common marmoset represents a better model than cotton-top marmosets for studying, in vivo, the role of c-myc and EBV in the pathogenesis of BL.
Materials and methods
Experimental animals Triplet common marmosets, two females (244 and 245) and one male (246), were used in these experiments. They were born and raised in a colony to which there have been no further additions since 1970.
removed from the plastic by incubation with 0.05°% trypsin, 0.02°% EDTA, washed and resuspended in 10 ml normal culture medium. After 48 h hygromycin B was added to 100 tg ml-'.
Serology
Serum samples were prepared from clotted peripheral blood taken at regular intervals under anaesthesia from each animal, and stored at -20C until required. Antibody titres against the EB viral capsid antigen (VCA) and early antigen
Cell culture M245 LCL is an EBV immortalised B cell line derived by infecting cells from the peripheral blood of marmoset number 245 with the M81 strain of EBV (Desgranges et al., 1976) which was isolated from a common marmoset LCL originally transformed by a strain of EBV derived from a nasopharyngeal carcinoma (de The et al., 1970) . Cells were cultured at 37°C in a 5% CO2 inctubator using RPMI 1640 containing 2mM L-glutamine, 100IU penicillin, 10lgmlm l streptomycin and 10% foetal calf serum (FCS). For transfections the amount of hygromycin B (Calbiochem) required to kill non-transfected cells (100 gml-') was determined by titration.
Plasmid DNA constructions pHEBoSVmycl,2,3 contains all three exons of the c-myc gene under control of the SV40 early region promoter (Lombardi et al., 1987) inserted into pHEBo, a plasmid which permits episomal replication in EBV infected B cells and selection with the antibiotic hygromycin B (Sugden et al., 1985) . pHEBoSVmycl,2,3 was a gift from Dr R. Dalla-Favera (New York University School of Medicine).
Liposome mediated transfection Liposome mediated transfection of M245 cells was carried out using a commercially supplied reagent (Lipofectin, BRL). Detection of plasmid-derived c-myc transcripts in M245-mycl23 using polymerase chain reaction (PCR). cDNAs were generated from total cellular RNA isolated from M245 and M245-mycl23 cell lines. Primers located in the SV40 early region promoter and exon II of c-myc c, were annealed to the cDNAs and sequences between the two primers amplified by PCR. The PCR products were electrophoresed on an agarose gel, transferred to a nylon membrane and probed with a 32P-labelled probe for c-myc. a, ethidium bromide stained gel prior to transfer. b, nylon membrane probed for c-myc sequences with 32P-labelled probe. (EA) were determined as described previously (Hotchin et al., 1989) . Heterophile antibody tests were performed using a commercially available procedure (Monospot, Mercia diagnostics).
Immunocytochemistry Detection of the Epstein-Barr virus nuclear antigen (EBNA) complex was performed using anti-complement immunofluorescence (ACIF) (Reedman & Klein, 1973) or anticomplement immunoperoxidase staining (ACIPx) (Guohua et al., 1981 Tumorigenicity assay
Growth of cells in semi-solid medium was determined as previously described (Hotchin et al., 1990 (Maniatis et al., 1982) and hybridised to 32p labelled pHEBoSVmycl,2,3 as described (Westneat et al., 1988) . 25 ng pHEBo-SVmycl,2,3 was labelled with 50 LCi 32P dCTP using a multiprime labelling system (Amersham).
Immunoblotting Whole cell protein extracts were prepared, separated by SDS-PAGE, transferred to nitrocellulose and immunoblotted as described previously (Allday et al., 1988; Rowe et al., 1987b ).
C-Myc was detected using a monoclonal antibody, Myc-9E10 (Evan et al., 1985) . Mycl-9E10 was a gift from Dr G. Evan (Imperial Cancer Research Fund, London) .
Results
Establishment of c-myc transfected marmoset LCL M245 LCL was transfected with pHEBo-SVmycl23 using Lipofectin and transfected cells selected with hygromycin B (100 tg ml-'). One drug resistant cell line was established (M245-mycl23). Attempts to obtain a pHEBoSV transfected control cell line proved unsuccessful and the parental M245 LCL was used as a control. To establish that the plasmid derived c-myc gene was being expressed in M245-mycl23 cells, cDNAs were generated from total RNA using reverse transcriptase. Plasmid derived transcripts were detected using PCR to amplify sequences encompassed by primers in the SV40 early region promoter/enhancer element and in the second exon of the c-myc gene (Figure 1c (Lombardi et al., 1987) . Our previous work has indicated that this is not necessarily the case, and this study further supports our basic observation that constitutive expression of c-myc in a lymphoblastoid cell is not sufficient to induce a tumorigenic phenotype (Hotchin et al., 1990) . In agreement with previously published reports (Lombardi et al., 1987; Hotchin et al., 1990) unlikely that these cells were derived from the inoculated cells since no circulating EBNA-positive cells were detected 84 days post-inoculation when the atypical cells represented 25% of the total lymphocyte count of marmoset 245. It is possible that the abnormal cells were a consequence of a pre-existing haematological disorder and cytogenetic studies have revealed a reciprocal chromosome translocation involving chromosomes 2 and 9 (J.A.B., unpublished observations). It is not known whether this translocation was present prior to the start of this experiment but it was not present in either of the other marmosets, nor in either of the cell lines used for inoculation. It seems unlikely, however, that this translocation was a consequence of inoculation of the myc-transfected cell line. The absence of EBNA-positive circulating B cells in any of the animals suggests that the inoculated cells were eliminated by the cell mediated immune system, presumably as a consequence of the cell lines expressing the EBV antigens known to be recognised by EBV-specific cytotoxic T lymphocytes (CTL), namely EBNA-2, EBNA-3, EBNA-6 and LMP (Thorley-Lawson & Israelsohn, 1987; Moss et al., 1988; Murray et al., 1990; Burrows et al., 1990a Burrows et al., , 1990b . This implies that constitutive high level expression of c-myc is insufficient to induce a phenotype capable of evading immunosurveillance either by down-regulation of viral proteins or other molecules involved in interactions with CTL. It would be interesting to attempt further experiments in which marmosets inoculated with myc-transfected cells were concurrently either immunosuppressed with cyclosporin A or infected with malaria. It is tempting to speculate that concurrent inoculation of myc-transfected cells and immunosuppression might result in the appearance of tumours similar to the EBV-associated lymphomas seen in humans with profound T cell dysfunction (Thomas et al., 1991) . If, as seems likely, the T cell dysfunction caused by malaria infection is not sustained following acute malaria (Whittle et al., 1984 ) then one would not expect such tumours to arise following malarial infection and inoculation of myc-transfected cells into marmosets.
